drugset / Trial / NCT04351516

Test and Treat COVID 65plus+

NCT04351516

Phase 2/3 Withdrawn University Hospital Tuebingen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of Hydroxychloroquine-levels will be performed on day 7, . A follow-up by video or telephone conference will be performed to observe drug intake and collect adverse events during treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7 days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/- 2 days).

Timeline

Start
2020-04-21
Primary completion
2020-12-31
Completion
2021-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 400 mg

Indications